Gilead Sciences ( GILD )

Share Interview Share Compensation

$3.2B

Peak10.2yr

Gilead's dominant revenue driver (46% of total revenue) anchoring the HIV franchise with 11-year patent protection remaining.

Help build intelligence for Gilead Sciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Leadership position in HIV/AIDS with BIKTARVY (peak sales, $3.2B Part D spending) and established franchise in hepatitis C with EPCLUSA and HARVONI offering deep therapeutic expertise.

Active hiring across 178 open roles, with growth in Commercial (38 openings), R&D (32), and Medical Affairs (19), signaling ongoing expansion despite recent restructuring.

Watch Out For

Significant recent restructuring: 448 cumulative layoffs across 9 WARN filings since January 2025, including Seattle facility closure (72 employees, Jan 2025) and Maryland layoffs (84 employees, Apr 2026).
Revenue concentration risk: 46% of revenue from single product (BIKTARVY) with patent LOE in 2036, plus peak-stage mature portfolio (EPCLUSA, GENVOYA, DESCOVY all at peak with LOE 2033–2036) leaves limited organic growth runway.

Generated by Claude from Gilead Sciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

EPCLUSA

Hepatitis C Virus

$877M

Peak7.9yr

Established hepatitis C franchise product at peak sales with 8-year remaining patent protection.

GENVOYA

$626M

Peak6.7yr

Established HIV combination therapy at peak lifecycle with 7-year patent protection.

DESCOVY

$590M

Peak9.8yr

Core HIV backbone product with strong 10-year patent protection and Part D spending of $590M.

ODEFSEY

Pulmonary Arterial Hypertension

$384M

Peak6.5yr

Established HIV regimen at peak with 7-year patent protection and $384M Part D spending.

VEMLIDY

Chronic Hepatitis B

$188M

Peak6.5yr

Hepatitis B monotherapy with 7-year remaining patent protection and $188M Part D spending.

LETAIRIS

$89M

Peak5.2yr

Endothelin receptor antagonist for PAH in peak phase with 5-year patent protection.

HARVONI

Hepatitis C Virus

$55M

Peak6.6yr

Hepatitis C pioneer now declining as EPCLUSA takes franchise share; approaching patent cliff in 2033.

Pipeline & Clinical Trials

WelTel

Pre-Exposure Prophylaxis (PrEP)

N/A

LDV/SOF

Hepatitis C Virus

N/A

Neurological and Cognitive Dysfunction Following CAR-T Treatment. ICANS and Beyond

CAR T Cell Therapy

N/A

PrEP-RN

N/A

NewSpringForMe digital solution

Hematologic Diseases

N/A

Digital nutritional program

Metabolic Dysfunction-Associated Steatotic Liver Disease

N/A

Biopsies and bloood samplings

N/A

Financial Incentive

Pre-Exposure Prophylaxis

N/A

B/F/TAF

N/A

The Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty'

HIV Positive

N/A

Virtual clinical visits with home lab kits and mailed HIV PrEP

N/A

TelePrEP

Hiv

N/A

A Surveillance Program for the Detection of Hepatitis B Virus (HBV) Resistance to Tenofovir in HIV-H

Absence of Signs or Symptoms

N/A

Biospecimen Collection

N/A

A chatbot designed to promote PrEP awareness and uptake for Black MSM

N/A

Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Naïve Infected Patien

Coronary Microcirculation

N/A

Rnalozine

N/A

COVID-19

Hematopathology Eligible or CAR-t Cell Treatment

N/A

A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjec

Limited Scleroderma

N/A

French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

N/A

Universal ART in a streamlined care model

Aspergillosis, Invasive Pulmonary

N/A

PCR based detection of azole resistance in A. fumigatus

N/A

Retrospective Audit

PrEP for Conception Purposes

N/A

There is no intervention

Diabetic Nephropathies

N/A

Thailand HDV Cohort

HDV

N/A

Hypertonic Saline

Healthy Subjects

N/A

PrEPception: Expanding Assisted Reproductive Options for Serodiscordant Couples

N/A

Digital Health Feedback System

N/A

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effe

N/A

Vuka+ application

Adherence, Medication

N/A

TruTag System

Hiv

N/A

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

N/A

Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)

N/A

WelTel

HIV Pre-exposure Prophylaxis

N/A

PrEP Care Anywhere Services

Adherence, Patient

N/A

PrEP Uptake with Rapid Start

N/A

I'm Fully Empowered for Her

N/A

Team Based Inpatient ARTAS

N/A

ELISA

N/A

Telehealth Coaching

Adolescent Behavior

N/A

Monitoring virus load

ART

N/A

HIV-HBV Co-Infection and Liver Disease

N/A

Colonoscopy

N/A

electronic medical record alert linked to orders

N/A

The RESPOND Outcomes Study

N/A

Gain framing plus demographically targeted photos

N/A

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Systemic Sclerosis

N/A

Genetic Determinants of Kidney Disease in People of African Ancestry With HIV

HIV Nephropathy

N/A

Diagnostic Study of Combined Biomnarker Testing in Bronchoalveolar Lavage Samples of Immunocompromis

Invasive Aspergillosis

N/A

HIV test by oral swab